宫颈癌近距离治疗中等剂量面体积:从标准A点向个体化影像引导自适应近距离治疗(EMBRACE I)的实践转变
基于EMBRACE I研究中1201例局部晚期宫颈癌患者,比较MR影像引导自适应近距离治疗(MR-IGABT)与经典A点标准加载的等剂量面体积(ISV)。结果显示MR-IGABT的V85 Gy、V75 Gy、V60 Gy EQD2中位数分别为72 cm³、100 cm³、233 cm³,V85 Gy中位数较标准A点85 Gy处方小23%,且ISV强烈依赖CTVHR体积,表明剂量适应按个体肿瘤大小及EBRT期间反应进行。
要点
- EMBRACE I中1201例局部晚期宫颈癌患者接受EBRT联合同步化疗后行MR-IGABT。
- V85 Gy、V75 Gy、V60 Gy EQD2中位数分别为72 cm³、100 cm³、233 cm³。
- V85 Gy中位数较标准A点85 Gy处方小23%,且ISV强烈依赖CTVHR体积。
核心结论
- EMBRACE I中MR-IGABT与个体化剂量处方相比经典A点标准计划改善了靶区剂量覆盖并降低了ISV。
- ISV强烈依赖CTVHR体积,表明剂量适应按个体肿瘤大小及EBRT期间反应进行。
研究设计与样本
- 分析EMBRACE I研究入组的1201例局部晚期宫颈癌患者。
- 患者接受外照射放疗(EBRT)联合同步化疗后行MR影像引导自适应近距离治疗(MR-IGABT)。
- ISV基于总参考空气比释动能(Total Reference Air Kerma)的预测模型计算,并与A点标准加载系统比较。
- 通过比较α/β 10 Gy与3 Gy的ISV评估分次方案与剂量率的影响。
主要发现
- V85 Gy、V75 Gy、V60 Gy EQD2中位数分别为72 cm³、100 cm³、233 cm³。
- V85 Gy EQD2中位数较标准A点85 Gy处方小23%。
- CTVHR体积<25 cm³、25-35 cm³、>35 cm³时V85 Gy分别为57 cm³、70 cm³、89 cm³。
- 38%的患者V85 Gy与A点75-85 Gy标准计划相似。
- 41%的患者V85 Gy小于A点75 Gy标准计划,21%的患者V85 Gy大于A点85 Gy标准计划。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To investigate the isodose surface volumes (ISVs) for 85, 75 and 60 Gy EQD2 for locally advanced cervix cancer patients. MATERIALS AND METHODS: 1201 patients accrued in the EMBRACE I study were analysed. External beam radiotherapy (EBRT) with concomitant chemotherapy was followed by MR based image-guided adaptive brachytherapy (MR-IGABT). ISVs were calculated using a predictive model based on Total Reference Air Kerma and compared to Point A-standard loading systems. Influence of fractionation schemes and dose rates was evaluated through comparison of ISVs for α/β 10 Gy and 3 Gy. RESULTS: Median V85 Gy, V75 Gy and V60 Gy EQD210 were 72 cm3, 100 cm3 and 233 cm3, respectively. Median V85 Gy EQD210 was 23% smaller than in standard 85 Gy prescription to Point A. For small (<25 cm3), intermediate (25-35 cm3) and large (>35 cm3) CTVHR volumes, the V85 Gy was 57 cm3, 70 cm3 and 89 cm3, respectively. In 38% of EMBRACE patients the V85 Gy was similar to standard plans with 75-85 Gy to Point A. 41% of patients had V85 Gy smaller than standard plans receiving 75 Gy at Point A, while 21% of patients had V85 Gy larger than standard plans receiving 85 Gy at Point A. CONCLUSIONS: MR-IGABT and individualized dose prescription during EMBRACE I resulted in improved target dose coverage and decreased ISVs compared to standard plans used with classical Point A based brachytherapy. The ISVs depended strongly on CTVHR volume which demonstrates that dose adaptation was performed per individual tumour size and response during EBRT.
引用
- Serban M, Kirisits C, Pötter R, et al. Isodose surface volumes in cervix cancer brachytherapy: Change of practice from standard (Point A) to individualized image guided adaptive (EMBRACE I) brachytherapy. Radiother Oncol. 2018. PMID: 30243671. doi:10.1016/j.radonc.2018.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。